Cargando…

Cisplatin-induced sudden cardiac death with hemodynamic collapse: a severe adverse drug reaction: Case report

RATIONALE: Cisplatin is responsible for a significant percentage of adverse drug reactions (ADRs) in oncology setting. A great proportion of cisplatin-induced severe adverse events are difficult to foresee, and giving premedication does not always prevent the occurrence of such events. PATIENT CONCE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abramavicius, Silvijus, Zemaitis, Marius, Pilvinis, Vidas, Kadusevicius, Edmundas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728816/ https://www.ncbi.nlm.nih.gov/pubmed/29310415 http://dx.doi.org/10.1097/MD.0000000000008995

Ejemplares similares

A case report and literature review: previously excluded tuberculosis masked by amiodarone induced lung injury
por: Karinauske, Egle, et al.
Publicado: (2018)

Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report
por: Abramavicius, Silvijus, et al.
Publicado: (2017)

Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors: A protocol for systematic review and meta-analysis
por: Li, Honglin, et al.
Publicado: (2020)

Novel Applications of NSAIDs: Insight and Future Perspectives in Cardiovascular, Neurodegenerative, Diabetes and Cancer Disease Therapy
por: Kaduševičius, Edmundas
Publicado: (2021)

Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer
por: Prieto-Callejero, Blanca, et al.
Publicado: (2020)

Adverse reactions and efficacy of camrelizumab in patients with lung adenocarcinoma with high PD-L1 expression: A case report
por: Wei, Tingting, et al.
Publicado: (2023)

An unusual presentation of multiple myeloma with unilateral sudden vision loss: A case report
por: Wu, Pei-Wen, et al.
Publicado: (2017)

Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Sen, Fatma, et al.
Publicado: (2016)

Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients
por: Wang, Yu, et al.
Publicado: (2017)

Lentinan combined with cisplatin for the treatment of non-small cell lung cancer
por: Zhao, Chenchen, et al.
Publicado: (2021)

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer
por: Hisakane, Kakeru, et al.
Publicado: (2017)

A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin
por: Cherniawsky, Hannah, et al.
Publicado: (2017)

The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer
por: Moon, Ji Young, et al.
Publicado: (2018)

A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma
por: Wang, Bi-Cheng, et al.
Publicado: (2019)

D-dimer can be a diagnostic marker for cisplatin-related aortic thrombosis: A case report
por: Matsumoto, Yu, et al.
Publicado: (2021)

Efficacy and safety of weekly versus triweekly cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma: A meta-analysis
por: Chen, Long, et al.
Publicado: (2022)

Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer
por: Yeon, Sang Hoon, et al.
Publicado: (2023)

Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study
por: Naujokaitis, Domas, et al.
Publicado: (2021)

Influence of Coadministration of Antithrombotic Medicines, Warfarin, and NSAIDs on Heparin Safety: Data from a Prospective Observational Study
por: Pranckeviciene, Gabriele, et al.
Publicado: (2013)

Cardiomyocyte Damage: Ferroptosis Relation to Ischemia-Reperfusion Injury and Future Treatment Options
por: Laukaitiene, Jolanta, et al.
Publicado: (2023)

Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic carcinoma: Case Report
por: Yang, Biao, et al.
Publicado: (2017)

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
por: Lee, Myung-Won, et al.
Publicado: (2020)

Efficacy and toxicity of three concurrent chemoradiotherapy regimens in treating nasopharyngeal carcinoma: Comparison among cisplatin, nedaplatin, and lobaplatin
por: Liang, Xuexia, et al.
Publicado: (2022)

Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients
por: Wang, Bing, et al.
Publicado: (2016)

Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review
por: He, Guangzhao, et al.
Publicado: (2016)

Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy
por: Chen, Chuanben, et al.
Publicado: (2017)

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
por: Tang, Wen-Hua, et al.
Publicado: (2020)

Sudden hemodynamic collapse after prone positioning on a Jackson spinal table for spinal surgery
por: Park, Jae Hong, et al.
Publicado: (2020)

A Phase II Study of Gemcitabine, Vincristine, and Cisplatin (Gvp) As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma
por: Luo, Zhiguo, et al.
Publicado: (2015)

Do Genetic Polymorphisms Modulate Response Rate and Toxicity of Cisplatin Associated With Radiotherapy in Laryngeal Squamous Cell Carcinoma?: A Case Report
por: Lopes-Aguiar, Leisa, et al.
Publicado: (2015)

S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial
por: Du, Feng, et al.
Publicado: (2015)

Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case–control study
por: Wu, Xin, et al.
Publicado: (2016)

Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis
por: Hu, Yongqi, et al.
Publicado: (2022)

Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report
por: Tang, Haifeng, et al.
Publicado: (2023)

High expression of HILPDA is an adverse prognostic prognostic factor in hepatocellular carcinoma
por: Wang, Xiao, et al.
Publicado: (2023)

Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade
por: Shen, Yanyun, et al.
Publicado: (2020)

The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis
por: Zhang, Jingyi, et al.
Publicado: (2021)

The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy in the treatment of locally advanced cervical carcinoma: An updated meta-analysis based on randomized controlled trials
por: Zhu, Jiahao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_is8j0pgbnemb5nid27nlsjjght